9EAJ

Structure of nanobody AT206 in complex with the angiotensin II type I receptor (AT1R)

9EAJ の概要

• エントリーDOI: 10.2210/pdb9eaj/pdb
• 関連するPDBエントリー: 9EAH 9EAI
• EMDBエントリー: 47833
• 分子名称: Nanobody AT206,Type-1 angiotensin II receptor,Soluble cytochrome b562, BAG2 Anti-BRIL Fab Heavy Chain, BAG2 Anti-BRIL Fab Light Chain (3 entities in total)
• 機能のキーワード: gpcr, at1r, nanobody, membrane protein
• 由来する生物種: Camelidae; 詳細
• タンパク質・核酸の鎖数: 4
• 化学式量合計: 179166.15

構造登録者

Skiba, M.A.,Kruse, A.C. (登録日: 2024-11-11, 公開日: 2025-03-05, 最終更新日: 2025-03-26)

主引用文献

Skiba, M.A.,Canavan, C.,Nemeth, G.R.,Liu, J.,Kanso, A.,Kruse, A.C.
Epitope-directed selection of GPCR nanobody ligands with evolvable function.
Proc.Natl.Acad.Sci.USA, 122:e2423931122-e2423931122, 2025

PubMed Abstract: Antibodies have the potential to target G protein-coupled receptors (GPCRs) with high receptor, cellular, and tissue selectivity; however, few antibody ligands for GPCRs exist. Here, we describe a generalizable selection method to enrich for GPCR ligands from a synthetic camelid antibody fragment (nanobody) library. Our strategy yielded multiple nanobody ligands for the angiotensin II type I receptor (AT1R), a prototypical GPCR and important drug target. We found that nanobodies readily act as allosteric modulators, encoding selectivity for both the receptor and chemical features of GPCR ligands. We then used structure-guided design to convert two nanobodies from allosteric ligands to competitive AT1R inhibitors through simple mutations. This work demonstrates that nanobodies can encode multiple pharmacological behaviors and have great potential as evolvable scaffolds for the development of next-generation GPCR therapeutics.

PubMed: 40067891
DOI: 10.1073/pnas.2423931122

実験手法

ELECTRON MICROSCOPY (3.2 Å)